Posted by Michael Wonder on 20 May 2024
Aprinoia Therapeutics announces fast track designation granted by US FDA to APN-1607 (florzolotau) for the diagnosis of progressive supranuclear palsy
20 May 2024 - Aprinoia Therapeutics today announced that on 8 May 2024, the US FDA granted fast track designation to APN-1607 (florzolotau), a positron emission tomography tracer for imaging tau protein in patients with suspected progressive supranuclear palsy.
APN-1607 is a radioactive fluorinated molecule developed to visualise and quantify 3R and 4R tau aggregates by positron emission tomography imaging across a number of diverse tau-related disorders, including progressive supranuclear palsy, frontotemporal dementia and Alzheimer’s disease, among others.
